FINAL AGENDA APRIL 28 - 29, 2012 The Boston Park Plaza Hotel & Towers | Boston, MA BIOLOGICS PHARMA-BIO PARTNERING FORUM PARTNERING FORUMS Emerging Antibody & Protein Engineering Focusing on the Right Partners REASONS TO ATTEND: NETWORK AND FOSTER BUSINESS with the companies that are going drive biologics growth over the next decade, as well those interested in funding its expansion IN-DEPTH PRESENtatIONS focused on promising technology platforms and innovative approaches in antibody therapies and protein engineering LEADING EARLY-StagE COMpaNIES hand-picked to present by top biologics experts from our Program Advisory Board TOP INDUSTRY EXECUTIVES, BIG PHARMA & INVESTORS in attendance, open to further business collaborations COVERAGE INCLUDES: • In Vivo Transgenic Antibody Platforms • Fusion Proteins • In Vitro Antibody Development Platforms • Protein Diversity • Antibody Tools • Human-Derived Antibodies • Novel Antibody Products in Development • Novel Protein Scaffolds • Bi-Specific and Multi-Specific Antibody • Screening and Design Platforms Technologies for Protein Engineering PREMIER SPONSORS Schedule one-on-one Co-Located with: partnering meetings via: Your networking tool to PARTNER DIRECT Successful Partnerships the essential protein engineering summit Organized by Cambridge Healthtech Institute PEGSummit.com/Antibody-Engineering-Partnering1 PROGRAM ADVISORY BOARD INCLUDES: Brian Atwood, M.B.A., Managing Director, Versant Robert Kastelein, Ph.D., Vice President, Biologics Hilde Revets, Ph.D., Senior Research Fellow, Ventures Strategy, Merck Research Labs Technology, Ablynx Sharon Cload, Ph.D., Vice President, Adnexus, Reid Leonard, Ph.D., Executive Director, Licensing, Barry Springer, Ph.D., Head of External Research Bristol Myers Squibb Merck Research Labs and Innovation, Biologics Research, Johnson & Jon Ellis, Ph.D., Vice President, Business Luke Li, M.D., Executive Director, Head of Global Johnson Development, Biopharmaceutical R&D BioTherapeutic Technologies, Pfizer Charles Wilson, Ph.D., Vice President, Global and Platform Technology & Science, GlaxoSmithKline Thomas Li, Ph.D., Senior Director, Technology, Roche Head of Strategic Alliances, Novartis Institutes for Richard Harkins, Ph.D., Principal Scientist, Global Diagnostics Biomedical Research Drug Discovery, Bayer Kia Motesharei, Ph.D., Vice President, Business Gordon Wong, Ph.D., Vice President, Business Healthcare Pharmaceuticals Development & Alliance Management, Dyax Corp. Development, Biogen-IDEC Margaret Karow, Ph.D., Executive Director, Protein Sciences, Amgen BIOLOGICS PARTNERING FORUM PRESENTERS: Dustin Armstrong, Ph.D., Vice President of Research, 4S3 Lee Henderson, Ph.D., Chief Executive Officer, Vybion, Inc. Andrew Rakestraw, Ph.D., Head of Technical Operations, Bioscience Paul Kang, Chief Scientific Officer, Innovative Targeting Protein Engineering, Celexion LLC Tom Barnes, Ph.D., Vice President, Discovery, Eleven Solutions, Inc. Mike Romanos, Ph.D., Chief Executive Officer, Crescendo Biotherapeutics, Inc. David King, Ph.D., Chief Scientific Officer, AnaptysBio Biologics Ltd. Julian Bertschinger, Ph.D., Chief Executive Officer, Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer, Joseph Rucker, Ph.D., Director of R&D, Integral Molecular Covagen NovImmune SA Inc. Roland Buelow, Ph.D., Chief Executive Officer, Open Allen Krantz, Ph.D., President and Chief Executive Officer, Sushma Shivaswamy, Ph.D., Director of Research & Monoclonal Technology, Inc. Advanced Proteome Therapeutics, Inc. Development, XBiotech Robert Burns, Ph.D., Chief Executive Officer, 4-Antibody Titus Kretzschmar, Ph.D., CSO Delenex Therapeutics AG Lesley Stolz, Ph.D., Vice President, Business Development, AG Sutro Biopharma, Inc. Volker Lang, Ph.D., Managing Director, AbCheck s.r.o. Bassil Dahiyat, Ph.D., Chief Executive Officer, Xencor, Inc. Kristine Swiderek, Ph.D., CSO & VP of Research, Casey Logan, M.B.A., Senior Vice President, Business Theraclone Sciences James R. Dasch, Ph.D., Chief Scientific Officer and Co- Development, Anaphone, Inc. Founder, Abazyme LLC Ali Tehrani, Ph.D., Chief Executive Officer, Zymeworks Nico Mertens, Ph.D., Director of Antibody Engineering, Davis Farmer, Chairman, Executive, MSM Protein Biotecnol, Inc. Mark Throsby, Ph.D., Chief Scientific Officer, Merus BV Technologies Sean McCarthy, Ph.D., M.B.A., Chief Executive Officer, Chris Ullman, Ph.D., Chief Scientific Officer, Isogenica Ltd. Barbara Fox, Ph.D., Chief Executive Officer, Avaxia CytomX Therapeutics, Inc. Mark Vaeck, Ph.D., Chief Executive Officer, Complix NV Biologics, Inc. Dinesh Patel, Ph.D., Chief Executive Officer, Protagonist Richard Wagner, Ph.D., Founder and Chief Scientific Katherine Griffiths, Ph.D.,Senior Scientist, Biochemistry, Therapeutics Officer, X-BODY BioSciences AdAlta / LaTrobe University David Rabuka, Ph.D., Chief Scientific Officer, Redwood Jin-San Yoo, Ph.D., Chief Executive Officer & President, Ulrich Haupts, Ph.D., Chief Scientific Officer, Affilin Bioscience, Inc. PharmAbcine, Inc. Technology, Scil Proteins GmbH Reserve your hotel room and SAVE $100 off your conference registration* *You must book your reservation under the Cambridge Healthtech/PEGS room block for a minimum of four nights Partner Direct is a networking tool designed to facilitatecollaboration amongst at The Boston Park Plaza Hotel & Towers. emerging companies and potential strategic partners. It is only available to The $100 discount is per room. registered attendees of the Bio-Pharma Partnering Forums. CHI employs partnering software so the audience will have the opportunity to sign up for one- *See page 7 for hotel and travel details* on-one meetings ahead of time with company presenters during the conference. For more information on CHI’s Partnering Forums please visit PharmaBioPartnering.com staY CONNECTED #PEGSBoston “The great thing about the PEGS meetings is not only the superb science, but the great networking and brainstorming opportunities.” - Premus 2 | the essential protein engineering summit PEGSummit.com Emerging Antibody & Protein Engineering BIOLOGICS PARTNERING FORUM Particularly efficient for promoting discussion of partnerships, Cambridge Healthtech Insititute’s Biologics Partnering Forum is designed for both the emerging companies with promising technology platforms and innovative approaches, as well as more established companies looking to collaborate as a way to gain access to novel technology and competitive products. Because of the focused nature and review process for selecting presenting companies, essentially every attendee will have significant shared interests with every other participant. SATURDAY, APRIL 28 been designed to reject molecules with less desirable drug characteristics as early as possible in the discovery process, and to deliver lead molecules 8:00am Registration and Morning Coffee for pre-clinical characterization which can be viewed as ‘development 9:00 Chairperson’s Opening Remarks ready’ early in discovery with a resulting enhanced likelihood of eventual biological and physiological success. In addition to partnering its 9:10 Panel Discussion: New Platforms for Antibody Discovery technology platform with corporate pharma, 4-Antibody is now applying its Retrocyte Display® technology in an R&D collaboration with the NOVEL TRANSGENIC DEVELOPMENT PLATFORMS Ludwig Institute for Cancer Research & the Memorial Sloan Kettering 9:40 MeMo® - A Transgenic Mouse for the Discovery of Cancer Center in New York to develop therapeutic antibodies directed to Innovative Human Antibody Therapeutics a series of molecular targets with key roles in the suppression of immune Mark Throsby, Ph.D., Chief Scientific Officer, Merus BV (www.merus.nl) responses in cancer patients. MeMo® is a transgenic mouse that produces human antibodies upon 10:40 Diversity Trap: Generating Monospecific Antibodies and immunization and that is engineered for ease of antibody lead selection Bispecific Kappa/Lambda-Bodies by Capturing Natural CDR3 and development. All MeMo® -derived antibodies are encoded by a single light chain V region. Antibodies derived from MeMo® are suitable for Diversity direct insertion into Merus’s proprietary bispecific IgG1 format or more Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer, NovImmune SA (www. complex proprietary combinatorial formats. Merus is developing a pipeline novimmune.com) of innovative human antibody therapeutics based on these technologies in The generation of diverse and functional antibody repertoires is key for the areas of oncology, inflammation and infectious disease. any in vitro selection technology for antibody discovery. The Diversity Trap approach that we have developed allows for the retrieval and capture 9:55 Development of a Unique Transgenic Mouse Platform to of CDRH3 or CDRL3 sequences from humans or other species, into Produce Human Single-Domain VH Antibody Fragments human antibody frameworks. This approach enables the generation of Mike Romanos, Ph.D., Chief Executive Officer, Crescendo Biologics Ltd. human antibody repertoires with a high level of functionality as well (www.crescendobiologics.com) as the creation of libraries biased against predefined targets. Diversity Crescendo is developing a transgenic mouse platform to generate high- Trap libraries support the development of both classical monospecific affinity human heavy chain antibodies, which readily yieldin vivo matured antibodies as well as NovImmune’s proprietary bispecific kappa/Lambda- single domain VH fragments requiring no humanisation. VH fragments are